Crown Bioscience LogoCrown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announced the milestone of completing 110 client projects on blood cancer treatments using models from their HuKemia collection.

“We are very proud to announce this accomplishment,” says Dr Henry Li, Vice President of Translational Oncology. “CrownBio’s ALL and AML patient-derived xenograft (PDX) models of different leukemia subtypes are unique in the commercial world, in that they are validated, stable models with typical leukemia symptoms and eventual mortality, and are truly representative of the human condition.”

“Other commercially available models are transient, non-transferable through passages (not renewable) and without disease symptom and mortality. While they can provide a gross measure of response, they have a finite banked leukemia source from patients. Thanks to the high quality of our models we keep registering a consistent growth in demand, which we are happy to meet with the highest standard of data quality,” said Li.

CrownBio’s permanent HuKemia models allow clients to follow disease recurrence after initial treatment challenge to test the efficacy of novel agents against drug resistance. “Transient models simply provide a one-shot study, whereas we have the ability to study both efficacy against primary and relapsed disease,” commented Li.

CrownBio plans to publish further papers on the latest results from the HuKemia collection in the near future. In the meantime, clients can access published data on all HuKemia models via HuBase, CrownBio’s proprietary database of PDX models.